

Update: Oncology gene and cell therapy drugs to be managed through the Oncology Value Management program starting Jan. 1

We updated this communication to include the HCPCS codes for the oncology gene and cell therapy drugs that use not otherwise classified HCPCS codes.

Starting Jan. 1, 2027, prior authorization requests for oncology gene and cell therapy drugs will be managed through the Oncology Value Management program, administered by OncoHealth. Prior authorizations for oncology gene and cell therapy drugs are currently managed by Blue Cross Blue Shield of Michigan and Blue Care Network.

We're making this change to align the management of prior authorizations for oncology services under OncoHealth. Starting Jan. 1, you'll be able to submit prior authorization requests for oncology services through a single portal for all members who require authorization through the Oncology Value Management program.

Affected members

The Oncology Value Management program, including the change outlined above, applies to the following members when services are received in Michigan or in other states:

- Blue Cross and BCN commercial
 - All fully insured members
 - Most self-funded groups — To determine which groups have opted out of the Oncology Value Management program, see the [Oncology Value Management program opt-out list for self-funded groups](#). (For members who don't require authorization through the Oncology Value Management program, be sure to check benefits before providing services.)

Note: This change doesn't affect UAW Retiree Medical Benefits Trust members with Blue Cross commercial plans. Continue to submit prior authorization requests for these members through the Medical and Pharmacy Drug PA Portal.

 - Members with individual coverage
- All Medicare Plus Blue and BCN Advantage members

Oncology gene and cell therapy procedure codes

As of the date of this publication, the following gene and cell therapy drugs require prior authorization and are affected by this change. This list is subject to change.

- | | |
|---|--|
| • Abecma [®] , HCPCS code Q2055 | • Omisirge [®] , HCPCS code J3406 |
| • Adstiladrin [®] , HCPCS code J9029 | • Ryoncil [®] , HCPCS code J3402 |
| • Amtagvi [®] , HCPCS code J9999 | • Tecartus [®] , HCPCS code Q2053 |

- Aucatzyl[®], HCPCS code Q2058
- Breyanzi[®], HCPCS code Q2054
- Carvykti[®], HCPCS code Q2056
- Kymriah[®], HCPCS code Q2042
- Tecelra[®], HCPCS code Q2057
- Tregzi[®], HCPCS code J3590
- Tudriqev[®], HCPCS code J9999
- Yescarta[®], HCPCS code Q2041

How to submit prior authorization requests

Starting Jan. 1, 2027, submit prior authorization requests to OncoHealth through the OncoHealth OneUM[™] portal or by calling OncoHealth at 1-888-916-2616.

Also starting Jan. 1, 2027, OncoHealth will accept retroactive authorization requests for gene and cell therapy drugs for dates of service up to one year prior to Jan. 1, 2027.

Additional information

For more information about the Oncology Value Management program, see the document titled [Oncology Value Management program through OncoHealth: Frequently asked questions for providers](#). We'll update this document to reflect this change by Jan. 1, 2027.

We'll also update the pertinent drug lists on **authorizations.bcbsm.com** to reflect this change by Jan. 1, 2027.

[Subscribe](#) to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.

OncoHealth is an independent company supporting Blue Cross Blue Shield of Michigan and Blue Care Network by providing cancer support services.